Clinical Trials
30 trialsLow-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
Sichuan University
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors
West China Hospital
A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
JS014 Combined With Toripalimab and TACE in Unresectable HCC: a Phase Ib Study
Xiangya Hospital of Central South University
Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies
Sichuan University
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced Pancreatic Cancer
Shanghai Junshi Bioscience Co., Ltd.
Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC
Hubei Cancer Hospital
Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.
Peking University
A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer
China Medical University, China
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients
Shanghai Jiao Tong University School of Medicine
Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer
Shanghai East Hospital
Neo-T in Treating Patients With Advanced Solid Tumors(GI-NeoT-03)
BGI, China
A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
A Clinical Study of TAB006 in Patients With Previously Treated, Advanced Malignancies
Shanghai Junshi Bioscience Co., Ltd.
Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma.
Sun Yat-sen University
The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor
Shanghai Junshi Bioscience Co., Ltd.
Combination Therapy for First Line Treatment of Advanced Cervical Cancer
Ruijin Hospital
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC
Fifth Affiliated Hospital, Sun Yat-Sen University
Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
Ruijin Hospital
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in Advanced Melanoma
Peking University Cancer Hospital & Institute
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
Shanghai Junshi Bioscience Co., Ltd.
Study of Autologous Cytotoxic T Lymphocyte Immunotherapy Combination With PD-1 Inhibitor in the Advanced NSCLC
Tianjin Medical University Cancer Institute and Hospital
A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma
Xiangya Hospital of Central South University
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of an Anti-PD-1 mAb for Patients With Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.